NBIX logo

NBIX Neurocrine Biosciences, Inc.

$143.18
$2.47
(1.75%)
Today
Closed $143.18
$0.78
(0.55%)
After Hours
54

Neutral Sentiment

How do you feel about NBIX?

Loading...
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference Neurocrine Biosciences to Present Research Advancing Understanding of...
PR Newswire
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical OfficerPR NewswireSAN DIEGO, Sept. 28, 2026 SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced...
PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September Neurocrine Biosciences to Present at Upcoming Investor Conferences in September PR Newswire SAN DIEGO, Sept. 2, 2026 SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced...
PR Newswire
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Zacks
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Zacks
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.
Zacks
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.
Zacks
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.
Zacks
Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'
Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported better-than-expected earnings. Rockwell Automation and Neurocrine Biosciences had mixed reactions from...
Benzinga